Free Trial
NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

Amgen logo
$264.00 +0.62 (+0.24%)
(As of 05:45 PM ET)

About Amgen Stock (NASDAQ:AMGN)

Key Stats

Today's Range
$260.87
$264.80
50-Day Range
$258.78
$325.28
52-Week Range
$253.30
$346.85
Volume
3.03 million shs
Average Volume
2.70 million shs
Market Capitalization
$141.91 billion
P/E Ratio
33.80
Dividend Yield
3.61%
Price Target
$319.67
Consensus Rating
Hold

Company Overview

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

Amgen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
89th Percentile Overall Score

AMGN MarketRank™: 

Amgen scored higher than 89% of companies evaluated by MarketBeat, and ranked 116th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amgen has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 10 buy ratings, 12 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Amgen has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amgen's stock forecast and price target.
  • Earnings Growth

    Earnings for Amgen are expected to grow by 4.20% in the coming year, from $19.53 to $20.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amgen is 33.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.36.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amgen is 33.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.05.

  • Price to Earnings Growth Ratio

    Amgen has a PEG Ratio of 2.91. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amgen has a P/B Ratio of 22.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.08% of the float of Amgen has been sold short.
  • Short Interest Ratio / Days to Cover

    Amgen has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Amgen has recently increased by 13.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Amgen pays a meaningful dividend of 3.42%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Amgen does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Amgen is 121.90%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Amgen will have a dividend payout ratio of 46.78% next year. This indicates that Amgen will be able to sustain or increase its dividend.

  • Read more about Amgen's dividend.
  • Percentage of Shares Shorted

    2.08% of the float of Amgen has been sold short.
  • Short Interest Ratio / Days to Cover

    Amgen has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Amgen has recently increased by 13.56%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Amgen has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Amgen this week, compared to 23 articles on an average week.
  • Search Interest

    70 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • MarketBeat Follows

    32 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 39% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amgen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.69% of the stock of Amgen is held by insiders.

  • Percentage Held by Institutions

    76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amgen's insider trading history.
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 12/2 - 12/6 (AMGN)
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025
Vials of liquid on a white table and the logo Amgen, large pharmaceutical company. March 15, 2021. Barnaul, Russia.
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Medicine background - stock image
2 Generic Drug Stocks Ready to Surge in 2025 (AMGN)
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
2 Excellent Dividend Stocks to Buy on the Dip
Amgen (NASDAQ:AMGN) Shares Gap Up - Should You Buy?
Amgen (NASDAQ:AMGN) Cut to Buy at StockNews.com
See More Headlines

AMGN Stock Analysis - Frequently Asked Questions

Amgen's stock was trading at $288.02 on January 1st, 2024. Since then, AMGN shares have decreased by 8.3% and is now trading at $264.00.
View the best growth stocks for 2024 here
.

Amgen Inc. (NASDAQ:AMGN) released its earnings results on Wednesday, October, 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year.
Read the conference call transcript
.

Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more.

Amgen's top institutional shareholders include State Street Corp (5.45%), Primecap Management Co. CA (2.65%), Geode Capital Management LLC (2.26%) and Charles Schwab Investment Management Inc. (1.96%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams.
View institutional ownership trends
.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol-Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/30/2024
Ex-Dividend for 12/9 Dividend
11/18/2024
Dividend Payable
12/09/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
26,700
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$319.67
High Stock Price Target
$405.00
Low Stock Price Target
$195.00
Potential Upside/Downside
+21.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
25 Analysts

Profitability

Net Income
$6.72 billion
Pretax Margin
14.38%

Debt

Sales & Book Value

Annual Sales
$32.53 billion
Cash Flow
$25.46 per share
Book Value
$11.65 per share

Miscellaneous

Free Float
533,824,000
Market Cap
$141.91 billion
Optionable
Optionable
Beta
0.55

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:AMGN) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners